$16.88+0.31 (+1.87%)
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.
Fortrea Holdings Inc. in the Healthcare sector is trading at $16.88. Wall Street consensus targets $16.21 (11 analysts), implying a -4.0% move over the next 12 months. The stock is currently near its 52-week high of $18.67, remaining 38.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as cl...
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Fortrea (NASDAQ:FTRE) and its peers.
Fortrea’s first quarter results were well received by investors, as the company exceeded Wall Street expectations on both revenue and non-GAAP earnings. Management attributed this performance to improved commercial execution in its core clinical research services, especially a rebound in biotech client activity and a higher book-to-bill ratio for the third straight quarter. CEO Anshul Thakral emphasized the impact of deliberate efforts to diversify the customer base, with notable wins among earl
Fortrea Holdings Inc. has reported past first-quarter 2026 results, with sales of US$636.5 million versus US$651.3 million a year earlier and a net loss of US$23.6 million, while also reiterating full-year 2026 revenue guidance of US$2.55 billion to US$2.65 billion. Although revenue edged lower year on year, the sharp reduction in quarterly net loss and reaffirmed revenue outlook directly addresses earlier concerns about Fortrea’s recent performance consistency. With Fortrea’s net loss...
Fortrea Holdings Inc. ( NASDAQ:FTRE ), is not the largest company out there, but it led the NASDAQGS gainers with a...